Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
Date:5/3/2011

d above. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the preparation and filing of a New Drug Application, the regulatory process to have the Company's LEVADEX product candidate approved for commercial use,  risks related to MAP Pharmaceuticals' future financial results and the potential benefits from the collaboration between MAP Pharmaceuticals and Allergan. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended December 31, 2010, available at http://edgar.sec.gov.

CONTACT: Christopher Y. Chai, Sr. Vice President and Chief Financial Officer of MAP Pharmaceuticals, Inc., (650) 386-3107; or media, Nicole Foderaro of WCG, (415) 946-1058, nfoderaro@wcgworld.com.MAP PHARMACEUTICALS, INC.(a development stage enterprise)CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)March 31,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents$

114,847$

76,007Accounts receivable70-Other current assets682644Total current assets115,59976,651Property and equipment, net5,8065,803Other assets2730Restricted investment310310Total assets$

121,742$

82,794LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable and accrued liabilities$

7,304$

12,440Debt5,6787,581Current portion of deferred revenue14,400-Total current liabilities27,38220,021Deferred revenue, less current portion11,439-Other liabil
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... According to the International Atomic Energy Agency (IAEA) ... terrorists acquiring sufficient quantities of plutonium or highly ... explosive device. The IAEA also notes that most ... quantities, which can be challenging to detect with ... study appearing this week in the Journal ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2
... , RESEARCH TRIANGLE PARK, N.C. , May 4 ... therapeutics, announced today that Kenneth I. Moch has ... Chimerix as Chief Operating Officer in July 2009 , ... and financing biomedical companies.  Mr. Moch will also join the ...
... May 4 PharmAthene, Inc. (NYSE Amex: PIP ), ... today announced that the Company,s Interim CEO, Eric I. Richman ... the critical interrelationship between government, academia and industry in the development ... , , ...
... Packing Record Tetrahedral dice, which have four ... yet tested, according to research performed by a collaboration ... revelation is the result of a series of experiments ... and adding more dice until the containers were completely ...
Cached Biology Technology:Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 2Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 3Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 4PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference 2Densest dice packing and computing with molecules 2
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... 3, 2014 Research and Markets ( ... "Global Gesture Recognition & Touch-Less Sensing (2D, ... 2020" report to their offering ... Recognition & Touch-Less Sensing Market to Grow Exponentially. ... while, but the companies were unable to leverage ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... NJ, March 20, 2013, John Wiley & Sons, Inc., ... Society (SPPS); a partnership which began over sixty years ... research journal Physiologia Plantarum , an international thought ... partnership began in 1948 when the society, known then ...
... uncovered from poorly explored areas of the Peruvian jungles. The ... before a dark brown and black background. It is assumed ... a slight difference in altitude ranges, which makes their biological ... was published in the open access journal Zookeys ...
... of the natural motors that are serving as models for ... therapeutic DNA, RNA or drugs into individual diseased cells. Their ... bacteria-killing virus and a new way to move DNA ... journal ACS Nano . Peixuan Guo and colleagues ...
Cached Biology News:The Scandinavian Plant Physiology Society and Wiley extend over 60 years of partnership 2Peru surprises with 2 new amazing species of woodlizards 2
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... component of the COP9 signalosome complex (CSN), ... developmental processes. The CSN complex is an ... pathway by mediating the deneddylation of the ... The complex is also involved in phosphorylation ...
... STAR3000 HISTAR detection systems provide linking ... used with species specific primary antibodies ... specimens. Visualisation is accomplished using an ... novel polymer labelling technology. Secondary antibodies ...
Biology Products: